Gene expression profiling of benign and malignant pheochromocytoma - PubMed (original) (raw)

doi: 10.1196/annals.1353.058.

Abdel G Elkahloun, Peter J Munson, Graeme Eisenhofer, Jennifer Barb, W Marston Linehan, Jacques W M Lenders, Ronald De Krijger, Massimo Mannelli, Robert Udelsman, Idris T Ocal, Barry L Shulkin, Stefan R Bornstein, Jan Breza, Lucia Ksinantova, Karel Pacak

Affiliations

Gene expression profiling of benign and malignant pheochromocytoma

Frederieke M Brouwers et al. Ann N Y Acad Sci. 2006 Aug.

Abstract

There are currently no reliable diagnostic and prognostic markers or effective treatments for malignant pheochromocytoma. This study used oligonucleotide microarrays to examine gene expression profiles in pheochromocytomas from 90 patients, including 20 with malignant tumors, the latter including metastases and primary tumors from which metastases developed. Other subgroups of tumors included those defined by tissue norepinephrine compared to epinephrine contents (i.e., noradrenergic versus adrenergic phenotypes), adrenal versus extra-adrenal locations, and presence of germline mutations of genes predisposing to the tumor. Correcting for the confounding influence of noradrenergic versus adrenergic catecholamine phenotype by the analysis of variance revealed a larger and more accurate number of genes that discriminated benign from malignant pheochromocytomas than when the confounding influence of catecholamine phenotype was not considered. Seventy percent of these genes were underexpressed in malignant compared to benign tumors. Similarly, 89% of genes were underexpressed in malignant primary tumors compared to benign tumors, suggesting that malignant potential is largely characterized by a less-differentiated pattern of gene expression. The present database of differentially expressed genes provides a unique resource for mapping the pathways leading to malignancy and for establishing new targets for treatment and diagnostic and prognostic markers of malignant disease. The database may also be useful for examining mechanisms of tumorigenesis and genotype-phenotype relationships. Further progress on the basis of this database can be made from follow-up confirmatory studies, application of bioinformatics approaches for data mining and pathway analyses, testing in pheochromocytoma cell culture and animal model systems, and retrospective and prospective studies of diagnostic markers.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eisenhofer G, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer. 2004;11:423–436. - PubMed
    1. Rao F, Keiser HR, O'connor DT. Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. Hypertension. 2000;36:1045–1052. - PubMed
    1. O'riordain DS, et al. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J. Surg. 1996;20:916–921. discussion 922. - PubMed
    1. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J. Urol. 1992;147:1–10. - PubMed
    1. Astuti D, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 2001;69:49–54. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources